Dupixent

<!-- Name:DistributionId Value:8843470 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

A logo on the Sanofi exhibition space at the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France June 15, 2022.Benoit Tessier | ReutersShares of Sanofi and Regeneron both…

<!-- Name:DistributionId Value:8793979 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

<!-- Name:DistributionId Value:8791865 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

<!-- Name:DistributionId Value:8790647 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

<!-- Name:DistributionId Value:8782894 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

<!-- Name:DistributionId Value:8738545 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

<!-- Name:DistributionId Value:8737493 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

Physician’s Briefing Staff FRIDAY, Sept. 30, 2022 (HealthDay News) -- The U.S. Food and Drug Administration approved Dupixent (dupilumab) as the first treatment for adults with prurigo nodularis,…

© Reuters. FILE PHOTO: Sanofi logo at the company's headquarters during the annual results news conference in Paris, France, February 4, 2022. REUTERS/Benoit Tessier By Ludwig Burger (Reuters) -French healthcare group Sanofi…